

January 25, 2013

**For Immediate Release**

Company name           Otsuka Holdings Co., Ltd.  
 Representative        Tatsuo Higuchi  
                               President and Representative Director, CEO  
 Code number         4578 First Section , Tokyo Stock Exchange  
 Inquiries             Takuma Kimura  
                               Director, Investors Relations Department

**Otsuka announces 2012 fourth quarter U.S. net sales figures of ABILIFY®**

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces 2012 fourth quarter U.S. net sales<sup>\*1</sup> figures of ABILIFY (aripiprazole), the antipsychotic agent discovered and marketed worldwide by its wholly owned direct subsidiary Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"). The results follow Bristol-Myers Squibb Company's ("Bristol-Myers Squibb") results announcement for fourth quarter 2012 on Thursday, January 24, 2013.

<sup>\*1</sup> Net sales in U.S. and Puerto Rico

ABILIFY is co-promoted in the U.S. by Otsuka America Pharmaceutical, Inc. ("OAPI," a wholly owned subsidiary of Otsuka Pharmaceutical) and Bristol-Myers Squibb. Net sales of ABILIFY is reported to OAPI; Otsuka Pharmaceutical pays Bristol-Myers Squibb a fee based on the collaboration agreement. 2012 fourth quarter U.S. net sales of ABILIFY reported to OAPI is \$1,230million.

**【OAPI U.S. Net Sales Figure of ABILIFY】**

| (\$ in millions) | 1 <sup>st</sup> Qtr | 2 <sup>nd</sup> Qtr | 3 <sup>rd</sup> Qtr | 4 <sup>th</sup> Qtr | Year   |
|------------------|---------------------|---------------------|---------------------|---------------------|--------|
| 2012             | 896                 | 1,068               | 1,015               | 1,230*              | 4,208* |
| % change         | - 0.1%              | 6.3%                | 3.3%                | 14.3%               | 6.3%   |
| 2011             | 897                 | 1,005               | 983                 | 1,076               | 3,960  |
| % change         | 6.4%                | 14.2%               | 18.3%               | 12.2%               | 12.7%  |

\* unaudited

The consolidated business forecast of fiscal 2012 announced by Otsuka Holdings on November 13, 2012 will not be changed.

**About ABILIFY:**

Discovered by Otsuka Pharmaceutical and jointly developed and commercialized by Otsuka and Bristol-Myers Squibb, ABILIFY is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.

To date, ABILIFY is sold in 60 countries and regions worldwide including Japan with global sales of 411.6 billion yen in fiscal 2011 accounting for 35.6% of Otsuka Holdings' consolidated results.

**About Otsuka Group:**

The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy "Otsuka-people creating new products for better health worldwide". The Otsuka Group has business operations in 25 countries and regions around the world, and its consolidated sales for fiscal 2011 is ¥1,154.6 billion.